The direct cost of patients with multiple sclerosis: A survey from Italian MS centres

P. Berto, M. P. Amato, P. Bellantonio, F. Bortolon, P. Cavalla, C. Florio, A. Lugaresi, E. Montanari, M. Rottoli, I. L. Simone, M. Zaffaroni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurological symptoms that carry a substantial burden. Previous Italian studies appear outdated, and investigation on the burden of recently marketed drug treatments should provide further economic evidence for policy makers. The objective of the study was to investigate patterns of care, resource consumption and direct medical cost of MS, in the perspective of the public health-care provider. Ten MS experts from public centres extracted and reported data of all MS patients seen during 2009, using a detailed questionnaire. The data of 8,326 MS patients were analysed: the course was relapsing-remitting in 5,376 (62%), secondary progressive in 1,798 (23%) and primary progressive in 691 (9%); 461 (6%) had a clinically isolated syndrome. The EDSS score was 0-3.5 in 5,118 (61%) patients, 4-6.5 in 2,408 (29%) and 7-9.5 in 800 (10%). The average cost of diagnosis (N = 694) was 1,236 ε/patient with large variations between centres due to the chosen diagnostic setting. The average direct medical cost for biological diseasemodifying drugs (bio-DMD) was 10,444 ε/patient/year (cost/patient by primary drug: 9,501 ε for interferon (IFN)-beta1a-im; 8,553 ε for IFN-beta1b; 11,255 ε for IFN-beta1a-sc44; 9,883 ε for IFN-beta1a-sc22; 8,174 ε for glatiramer acetate (GA); 21,817 ε for natalizumab) and 3,151 ε for non-bio-DMD. The cost of diagnosis is largely influenced by care setting, due to local health-care provision patterns. The annual medical cost/patient is largely driven by the cost of drugs (89.2% of total); GA represents the least expensive bio-DMD in the Italian health-care setting.

Original languageEnglish
Pages (from-to)1035-1041
Number of pages7
JournalNeurological Sciences
Volume32
Issue number6
DOIs
Publication statusPublished - 2011

Fingerprint

Multiple Sclerosis
Costs and Cost Analysis
Interferons
Pharmaceutical Preparations
Delivery of Health Care
Drug Costs
Surveys and Questionnaires
Administrative Personnel
Health Personnel
Chronic Disease
Public Health
Economics

Keywords

  • Cost
  • Disease-modifying biologics
  • Italy
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Berto, P., Amato, M. P., Bellantonio, P., Bortolon, F., Cavalla, P., Florio, C., ... Zaffaroni, M. (2011). The direct cost of patients with multiple sclerosis: A survey from Italian MS centres. Neurological Sciences, 32(6), 1035-1041. https://doi.org/10.1007/s10072-011-0578-4

The direct cost of patients with multiple sclerosis : A survey from Italian MS centres. / Berto, P.; Amato, M. P.; Bellantonio, P.; Bortolon, F.; Cavalla, P.; Florio, C.; Lugaresi, A.; Montanari, E.; Rottoli, M.; Simone, I. L.; Zaffaroni, M.

In: Neurological Sciences, Vol. 32, No. 6, 2011, p. 1035-1041.

Research output: Contribution to journalArticle

Berto, P, Amato, MP, Bellantonio, P, Bortolon, F, Cavalla, P, Florio, C, Lugaresi, A, Montanari, E, Rottoli, M, Simone, IL & Zaffaroni, M 2011, 'The direct cost of patients with multiple sclerosis: A survey from Italian MS centres', Neurological Sciences, vol. 32, no. 6, pp. 1035-1041. https://doi.org/10.1007/s10072-011-0578-4
Berto, P. ; Amato, M. P. ; Bellantonio, P. ; Bortolon, F. ; Cavalla, P. ; Florio, C. ; Lugaresi, A. ; Montanari, E. ; Rottoli, M. ; Simone, I. L. ; Zaffaroni, M. / The direct cost of patients with multiple sclerosis : A survey from Italian MS centres. In: Neurological Sciences. 2011 ; Vol. 32, No. 6. pp. 1035-1041.
@article{fd59f3c8f0264065bd3264001d3cdbf2,
title = "The direct cost of patients with multiple sclerosis: A survey from Italian MS centres",
abstract = "Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurological symptoms that carry a substantial burden. Previous Italian studies appear outdated, and investigation on the burden of recently marketed drug treatments should provide further economic evidence for policy makers. The objective of the study was to investigate patterns of care, resource consumption and direct medical cost of MS, in the perspective of the public health-care provider. Ten MS experts from public centres extracted and reported data of all MS patients seen during 2009, using a detailed questionnaire. The data of 8,326 MS patients were analysed: the course was relapsing-remitting in 5,376 (62{\%}), secondary progressive in 1,798 (23{\%}) and primary progressive in 691 (9{\%}); 461 (6{\%}) had a clinically isolated syndrome. The EDSS score was 0-3.5 in 5,118 (61{\%}) patients, 4-6.5 in 2,408 (29{\%}) and 7-9.5 in 800 (10{\%}). The average cost of diagnosis (N = 694) was 1,236 ε/patient with large variations between centres due to the chosen diagnostic setting. The average direct medical cost for biological diseasemodifying drugs (bio-DMD) was 10,444 ε/patient/year (cost/patient by primary drug: 9,501 ε for interferon (IFN)-beta1a-im; 8,553 ε for IFN-beta1b; 11,255 ε for IFN-beta1a-sc44; 9,883 ε for IFN-beta1a-sc22; 8,174 ε for glatiramer acetate (GA); 21,817 ε for natalizumab) and 3,151 ε for non-bio-DMD. The cost of diagnosis is largely influenced by care setting, due to local health-care provision patterns. The annual medical cost/patient is largely driven by the cost of drugs (89.2{\%} of total); GA represents the least expensive bio-DMD in the Italian health-care setting.",
keywords = "Cost, Disease-modifying biologics, Italy, Multiple sclerosis",
author = "P. Berto and Amato, {M. P.} and P. Bellantonio and F. Bortolon and P. Cavalla and C. Florio and A. Lugaresi and E. Montanari and M. Rottoli and Simone, {I. L.} and M. Zaffaroni",
year = "2011",
doi = "10.1007/s10072-011-0578-4",
language = "English",
volume = "32",
pages = "1035--1041",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "6",

}

TY - JOUR

T1 - The direct cost of patients with multiple sclerosis

T2 - A survey from Italian MS centres

AU - Berto, P.

AU - Amato, M. P.

AU - Bellantonio, P.

AU - Bortolon, F.

AU - Cavalla, P.

AU - Florio, C.

AU - Lugaresi, A.

AU - Montanari, E.

AU - Rottoli, M.

AU - Simone, I. L.

AU - Zaffaroni, M.

PY - 2011

Y1 - 2011

N2 - Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurological symptoms that carry a substantial burden. Previous Italian studies appear outdated, and investigation on the burden of recently marketed drug treatments should provide further economic evidence for policy makers. The objective of the study was to investigate patterns of care, resource consumption and direct medical cost of MS, in the perspective of the public health-care provider. Ten MS experts from public centres extracted and reported data of all MS patients seen during 2009, using a detailed questionnaire. The data of 8,326 MS patients were analysed: the course was relapsing-remitting in 5,376 (62%), secondary progressive in 1,798 (23%) and primary progressive in 691 (9%); 461 (6%) had a clinically isolated syndrome. The EDSS score was 0-3.5 in 5,118 (61%) patients, 4-6.5 in 2,408 (29%) and 7-9.5 in 800 (10%). The average cost of diagnosis (N = 694) was 1,236 ε/patient with large variations between centres due to the chosen diagnostic setting. The average direct medical cost for biological diseasemodifying drugs (bio-DMD) was 10,444 ε/patient/year (cost/patient by primary drug: 9,501 ε for interferon (IFN)-beta1a-im; 8,553 ε for IFN-beta1b; 11,255 ε for IFN-beta1a-sc44; 9,883 ε for IFN-beta1a-sc22; 8,174 ε for glatiramer acetate (GA); 21,817 ε for natalizumab) and 3,151 ε for non-bio-DMD. The cost of diagnosis is largely influenced by care setting, due to local health-care provision patterns. The annual medical cost/patient is largely driven by the cost of drugs (89.2% of total); GA represents the least expensive bio-DMD in the Italian health-care setting.

AB - Multiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurological symptoms that carry a substantial burden. Previous Italian studies appear outdated, and investigation on the burden of recently marketed drug treatments should provide further economic evidence for policy makers. The objective of the study was to investigate patterns of care, resource consumption and direct medical cost of MS, in the perspective of the public health-care provider. Ten MS experts from public centres extracted and reported data of all MS patients seen during 2009, using a detailed questionnaire. The data of 8,326 MS patients were analysed: the course was relapsing-remitting in 5,376 (62%), secondary progressive in 1,798 (23%) and primary progressive in 691 (9%); 461 (6%) had a clinically isolated syndrome. The EDSS score was 0-3.5 in 5,118 (61%) patients, 4-6.5 in 2,408 (29%) and 7-9.5 in 800 (10%). The average cost of diagnosis (N = 694) was 1,236 ε/patient with large variations between centres due to the chosen diagnostic setting. The average direct medical cost for biological diseasemodifying drugs (bio-DMD) was 10,444 ε/patient/year (cost/patient by primary drug: 9,501 ε for interferon (IFN)-beta1a-im; 8,553 ε for IFN-beta1b; 11,255 ε for IFN-beta1a-sc44; 9,883 ε for IFN-beta1a-sc22; 8,174 ε for glatiramer acetate (GA); 21,817 ε for natalizumab) and 3,151 ε for non-bio-DMD. The cost of diagnosis is largely influenced by care setting, due to local health-care provision patterns. The annual medical cost/patient is largely driven by the cost of drugs (89.2% of total); GA represents the least expensive bio-DMD in the Italian health-care setting.

KW - Cost

KW - Disease-modifying biologics

KW - Italy

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84942303215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942303215&partnerID=8YFLogxK

U2 - 10.1007/s10072-011-0578-4

DO - 10.1007/s10072-011-0578-4

M3 - Article

AN - SCOPUS:84942303215

VL - 32

SP - 1035

EP - 1041

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 6

ER -